Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Rivia launches AI-powered clinical trial data review module, with Scancell as early adopter
(1h)
Valo and Montai become one as the Flagship AI-based biotechs tie the knot
(4h)
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
(5h)
Amgen builds Sjögren’s case with detailed phase 3 data ahead of Novartis showdown
(6h)
Capricor, NextCure reveal recent layoffs as they gear up for approval decision, merger
(9h)
Abbott nabs FDA approval, CE Mark for implantable cardioverter-defibrillator lead
(12h)
Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
(22h)
Start Center for Cancer Research opens first early-phase clinical trial site in Italy
(1d)
PepGen’s stock doubles as midphase muscle dystrophy data wow analysts
(1d)
AstraZeneca buys partner Omniose for bacterial vaccine technology
(1d)
BioPharma Dive
Drug price hikes in Germany could push US costs higher, study says
(3h)
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
(5h)
PepGen soars on promising early data for muscular dystrophy drug
(21h)
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
(1d)
London biotech Oyster harvests $60M for tau-targeting brain drugs
(1d)
BIO unveils plan for US to remain biotech’s ‘global leader’
(1d)
Bayer wins FDA nod for a new kind of blood thinner
(1d)
Vir hepatitis D drug succeeds in first pivotal study
(2d)
Argenx to buy peptide platform in potentially billion-dollar deal
(2d)
Ramaswamy’s biotech baggage haunted his political run
(2d)
Endpoints News
Flagship merges two startups; J&J scores a bipolar mania success
(3h)
Beeline reveals Phase 2 lupus data from old Bristol Myers drug
(5h)
UK science minister calls for more life sciences investment
(5h)
VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseases
(6h)
Merck KGaA lands FDA nod for joint tumor drug it licensed from Abbisko
(7h)
Despite midterm losses, RFK Jr. is bullish on MAHA's future
(21h)
Mirum plans FDA submission for hepatitis D treatment as competition brews
(23h)
Oura to buy AI care startup Counsel Health for $625M
(1d)
Democrats ramp up oversight of MFN deals after midterm wins
(1d)
Beam says base-edited sickle cell therapy succeeds in Phase 1/2 study
(1d)
BioSpace
FDA warns Chinese providers of compounding APIs over record-request refusals
(2h)
PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing
(3h)
Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
(4h)
Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapy
(4h)
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
(8h)
China has a clear shot to 2030 goals, though economic, cultural barriers remain
(13h)
Without US action on China’s innovation blitz, biotech leaders see a Rust Belt future
(13h)
FDA's rare disease framework faces its first real test in Capricor’s DMD drug
(1d)
Coherus cuts 30% of staffers, Gyre makes post-acquisition layoffs
(1d)
BIO pitches US plan to beat China in biotech ‘space race’
(1d)
STAT News
What MAHA’s support for Russell Brand tells us about the movement
(1h)
BMI alternative would flip obesity diagnosis for millions, study finds
(3h)
Why this former ER doc thinks giving AI less information is sometimes better
(3h)
Senate health committee schedules vote on FDA commissioner nominee Overton
(4h)
We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more
(4h)
The U.S. may soon lose measles elimination status
(6h)
MDCalc launches a ‘rumble strip’ for doctors using generative AI tools
(9h)
Doctors on Kennedy’s influential preventive care panel have major conflicts of interest, filings reveal
(9h)
A new tactic in the war over out-of-network bills: Health care providers are suing employers
(9h)
Low-income parents can’t afford to take chances with nutritious food their picky eaters might reject
(9h)
BioPharma Trend
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Tzuchman-Katz
(1d)
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Zucman-Katz
(2d)
The $1.8 Billion Bet That More Data Will Enable Progress in Virtual Cells
(1w)
The Virtual Cell Tracker: Who’s Building Them, What Works, Where the Money Goes
(1w)
Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying Customers
(2w)
Benchling’s Science Foundries put teams of AI agents in charge of whole R&D workflows
(4w)
When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still Decides
(1mo)
WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene Therapies
(1mo)
The $2.7B Question: How Do We Know If Isomorphic's AI Works?
(1mo)
Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line
(1mo)
Drug Channels
The State of Employer Pharmacy Benefits in 2026: When Plan Savings Come From Higher Patient Costs
(1d)
BlinkRx Insights: Clarifying the Mystery around “DTP”
(5d)
Disintegration: Adam’s Four Takeaways from the CVS Health Breakup
(6d)
Drug Channels Outlook 2027: Adam’s Final Webinar
(1w)
Biopharma’s AI Fork in the Road
(1w)
"How Do I Know I'm Not Just Giving Money Away?" The Question Every Market Access Leader Is Asking
(2w)
Drug Channels News Roundup, October 2026: Part D’s Hidden Cost Sharing Gap, 340B’s $244 Billion Footprint, The Net Price Rebate Model, Cigna’s Wholesale Push, and Four Ways to Bag a Drug
(2w)
Copay + GTN Revenue Protection = Better Together
(3w)
Alternative PBM Satisfaction Declined in 2026, Shrinking the Advantage Over the Big Three PBMs
(3w)
Informa's Trade and Channel Strategies
(3w)
European Biotechnology Magazine
VectorY secures €74.5M to advance ALS gene therapy trial
(5h)
Austria builds life sciences momentum
(5h)
SRTD raises €31.5M seed round to develop cell-selective RNA therapies
(1d)
Swiss VC Redalpine closes eighth fund at $250 million
(1d)
Boehringer-Zealand obesity drug clears cardiovascular safety hurdle, but tolerability concerns remain
(1d)
Oyster Therapeutics raises $60M to bring Alzheimer’s tau degrader to clinic
(1d)
Novo, Novartis drugs cut heart-risk markers but not cardiovascular events
(1d)
Windward targets $204M IPO; Valneva’s Shigella vaccine meets Phase 2 endpoint; Ethris’ nasal mRNA lowers viral load
(1d)
Neobe raises $6.8M to break tumor barriers with bacteria
(1d)
Immunocore doubles up on T-cell engagers in eye cancer
(2d)
Drug Hunter
DNA-Encoded Libraries Expand the Reach of Hit Discovery
(3h)
GSK3882347
(1d)
Thinking Outside of the Taxonomic Box: Non-Traditional In Vivo Species in Drug Discovery
(2d)
Lenacapavir, a First-in-Class HIV Capsid Inhibitor for the Treatment and Prevention of HIV-1 Infection
(2d)
Chronic CRFR2 Agonism for Muscle-Sparing Weight Loss
(5d)
RG6182
(6d)
A Deep Dive into INN Proposed List 135 Part 2 (M–Z)
(1w)
A Deep Dive into INN Proposed List 135 Part 1 (A–L)
(1w)
Two Fluorines, One Carbon, Many Possibilities
(1w)
September 2026 Patent Gazette
(2w)
Labiotech.EU
Preclinical Pulse: The research catching our eye in November 2026
(1d)
Zooming out from ovaries: how has renaming PMOS changed lives?
(5d)
How to turn a BIO-Europe meeting into a lasting partnership
(5d)
From gene editing to RNA therapies: The biotech trends to look out for at AHA Scientific Sessions 2026
(1w)
The biggest biotech funding rounds in October 2026
(1w)
Top biotech deals in October 2026
(1w)
Why global expansion is changing the shape of the ATMP supply chain
(1w)
Teva’s pipeline in 2027: Can it sustain its transformation?
(1w)
ESMO 2026: readouts and highlights at the oncology summit
(2w)
Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
(2w)
Bio IT World
Biosecurity Is Too Important to Be Left Unregulated
(13h)
NCOA7 Emerges as Drug Target Linking Pulmonary Hypertension to Brain Inflammation
(1d)
Fresenius WuXi Biologics Partner, Pfizer Deploys Edison's AI Scientist, Ultima, Illumina Win Singapore National Sequencing Award
(4d)
Gxp Compliance Support Is Coming To The Public Cloud. That’s Good For Life Sciences
(6d)
Quantifying the Average Human Genome
(1w)
Regulatory Affairs Is the Connective Tissue Pharma’s AI Strategy Is Missing
(2w)
Follow the Money: OMass Raises Series C, Pathos AI Drug Development, Owkin Alums Launch Rivercell
(2w)
ParkourSC Acquires Quartic, PacBio Partners with Verily, CAS Data Arrives in Microsoft Copilot
(2w)
Innovating at Speed in an Underrated Drug-Making Process
(3w)
Inside the ‘Public Library of Blueprints’: How the ASAP Discovery Consortium Turned Open Science Into an Antiviral Pipeline
(3w)
GEN News
How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years
(1d)
From Farm Waste to Medical Nanoparticles
(1d)
Hybrid Model Captures Lactate Run-Away and Back-Metabolism
(1d)
Extracellular Vesicle Product Developer Creates Potency Assay
(1d)
Automation a Path to Lower Cell Therapy Costs
(1d)
Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition
(1d)
Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research
(1d)
How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome
(2d)
Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests
(2d)
New AI Models Are Turbo-Charging Protein Design
(2d)
Cure Today
Living With BRCA and Ovarian Cancer: Leanne Citrone's Story
(1h)
Patient Advocacy Advice From a Colon Cancer Survivor
(3h)
Medicare Part D 2027: What a $2,400 Cap Means for Cancer Drugs
(5h)
Inside the Clinic: How One Hematologist Approaches a Rare Leukemia
(22h)
The Day I Tapped My Son Out of Basic Training
(23h)
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
(1d)
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
(1d)
Why Rituxan Plus Cladribine May Delay Hairy Cell Leukemia Relapse
(1d)
Glioblastoma Patients Can Request Genomic Testing on Their Tumor Tissue
(1d)
Weight Loss With Pancreatic Cancer: Why It Happens and What Helps
(2d)
Contract Pharma
Devia Spins Out of Visium to Aid Pharma Companies with GxP Deviations
(50m)
FDA Approves Merck, Darmstadt, Germany’s Pimjetmi for Symptomatic TGCT
(2h)
T-Cypher Bio Expands Oxford Operations with Move to Abingdon Science Park
(2h)
Körber Launches Cloud-Native PAS-X Neo MES for Smaller Pharma Manufacturers
(4h)
QbDVision Appoints Christoph Pistek as VP, Digital CMC Solutions
(4h)
Circio, Solid Biosciences Partner on Next-Generation Cardiac Gene Therapy
(5h)
Novacyt’s Yourgene Wins Australian Approval for DPYD Chemotherapy Toxicity Test
(5h)
ProBio, AbTis Enter License Agreement for Next-Gen ADC Asset Development
(21h)
AGC Biologics, Child’s Cure Genetic Research Partner on mRNA Discovery for Rare Epileptic Disorder
(22h)
ProBioGen Berlin Viral Manufacturing Facility Gets Extended Authorization, Updated GMP Certificate
(1d)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1mo)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1mo)
Zerion partner files first EU application for Dispersome‑enabled product
(1mo)
Tozorakimab shows broad COPD benefit in new phase 3 data
(1mo)
Study highlights advance in influenza protection for older adults
(2mo)
NICE backs daratumumab quadruplet for transplant‑eligible myeloma
(2mo)
Teitur reports positive early data for Parkinson’s peptide TT‑P34
(2mo)
Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer
(2mo)
NICE backs ibrutinib regimen for untreated mantle cell lymphoma
(2mo)
Livdelzi accepted in Scotland for treatment of PBC
(2mo)
Medcity News
Follow the Leader: How to Build and Retain Great Clinical Teams
(5h)
Oura’s Buys Counsel for $625M, But Will Payers and Consumers Get on Board?
(19h)
FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke
(22h)
New Campaign Wants AI Applications To Look Beyond Speed
(1d)
The Laboratory Industry’s Next Competitor May Be the Company on Your Patient’s Wrist
(1d)
Startup Supporting Caregivers Raises $3.5M in Seed Funding
(1d)
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
(1d)
Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
(1d)
Simulation-Guided Clinical Trials: Is EU Law Ready?
(2d)
Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
(2d)
Chemical & Engineering News
Sorry, it’s a scam—what to look out for in your job search
(23m)
Periodic Graphics: Fighting flu: How flu vaccines are made
(2h)
C&EN Chempics Close-Ups, Nov. 11
(6h)
California voters OK $8.4 billion for immunology amid funding questions
(21h)
Business Watch: 3M settles PFAS cases for $7.35 billion, and more
(23h)
ACS Board elects Carolyn Ribes as 2027 chair
(1d)
Green chemistry sector navigates China’s influence
(1d)
Nominations sought for 2027 Crano Memorial Lecture
(1d)
First cohort of ACS-Moore Postdoctoral Bridge Award in Quantum Materials recipients announced
(1d)
No, drug outsourcing firms haven’t abandoned the small molecule
(1d)
The Pharma Letter
VectorY raises 74.5 million euros to take TDP-43 ALS therapy through Phase I/II readout
(1h)
Teva targets $6-7 billion innovative medicines revenue by 2030 at first R&D Day
(3h)
Positive new Phase III data for Amgen’s dazodalibep
(4h)
Shionogi enters license agreement with Link for cefiderocol
(5h)
Kesmalea rebrands as Oyster with $60 million, Lilly-backed round for oral tau degrader
(5h)
Kesmalea rebrands as Oyster with $60 million, Lilly-backed round for oral tau degrader
(5h)
Circio and Solid Bio collaborate for genetic heart disease technology
(6h)
China tightens IIT oversight to safeguard CGT data integrity
(7h)
Nuformix proposes acquisition of Biovara
(7h)
J&J’s Caplyta meets endpoints in second Phase III bipolar mania study, supporting planned FDA filing
(7h)
Targeted Oncology
Dr Garmezy on JNJ-6143's Novel Mechanism in Advanced Prostate Cancer
(19m)
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
(1h)
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
(2h)
Novocure’s Optune Mya Gets FDA Not Approvable Letter
(3h)
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
(4h)
Physician and Practice Factors Shape Advanced Cancer Trial Enrollment
(4h)
Significance of the All-Comer PD-L1 CPS Design
(6h)
OrigAMI-5 Design Rationale for First-Line Use
(6h)
Oncologists Discuss Ibrutinib Switching and Fixed-Duration Therapy in CLL
(21h)
Dr Shitara on Selecting First-Line Therapy in HER2+ GEA
(23h)
MedWatch
Trump’s drug pricing policy could delay new medicines in Europe
(5h)
Two boards are plenty for Lundbeck CEO: “It’s about becoming a better CEO”
(6h)
Lundbeck CEO plays down margin pressure from Vyepti’s success
(6h)
Moderna CEO sees personalized cancer vaccine as potential best-seller
(8h)
Lilly to seek FDA approval for Foundayo in sleep apnea after strong Phase 3 data
(9h)
Olympus raises outlook on stronger GI endoscope sales
(1d)
Zealand partner reports positive heart safety results for obesity drug candidate
(1d)
FDA orders eye disease warning on Novo and Eli Lilly obesity drugs
(1d)
Gubra CEO out after just over a year in the job
(1d)
Lundbeck sharply raises 2026 outlook
(1d)
In The Pipeline
Think Before You Degrade
(21h)
Jon Clardy, 1943-2026
(2d)
Antimicrobial Peptides for Fun (?) and Profit (?)
(6d)
The Morning After the Midterms
(7d)
Taming Photochemistry
(1w)
Chemotherapy Actually Helps Immunotherapy in Cancer
(1w)
Messing Around With the Warburg Effect
(2w)
Lipidation and Its Discontents
(2w)
What Does It Mean to "Know Medicinal Chemistry"?
(2w)
The Merck/Moderna Results
(3w)
Pharmaphorum
Obesity needs a new clinical definition, study finds
(5h)
Google Cloud launches Gemini for Healthcare
(6h)
UK's Levicept builds case for osteoarthritis therapy at ACR
(7h)
AZ boosts vaccine capabilities with Omniose buy
(8h)
Merck's rare tumour drug Pimjetmi claims FDA approval
(9h)
Third Rock in $2bn drug-hunting pact with China's Funnel
(1d)
UK's Oyster Tx rebrands and raises $60m for Alzheimer's RD
(1d)
Hims & Hers to offer unapproved peptides to customers
(1d)
FDA orders blindness risk warning to GLP-1 agonist labels
(1d)
Bayer bags FDA green light for stroke drug Sunharbo
(1d)
Drug Discovery Weekly
UQ technology opens new front in Alzheimer’s and Parkinson’s
(2w)
Why we need to rethink childhood cancer treatments
(2w)
Q3 UK biotech VC heads for record year thanks to megadeals
(2w)
Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers
(2w)
New webinar: Applying ultrasensitive immunoassays for clinical biomarkers
(2w)
Partnership advances AI-driven R&D collaboration
(2w)
The three generations of obesity medicines
(2w)
Webinar: Exploring warm PDX benefits and onsite expertise
(2w)
Beyond the model: Exploring warm PDX benefits and onsite expertise
(2w)
ScionxBio collaborates to develop long-acting xRNA therapeutics
(2w)
HIT Consultant
WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans
(7h)
TigerConnect Smart Room Suite: Integrating Epic, Cloud Alarm Management, and Bedside AI
(13h)
Oscar Health and HealthEx Leverage TEFCA Individual Access to Bring Medical Records into AI Workflows on Day One
(14h)
How Real-World Data (RWD) Is the Turning Point for Pharma Innovation
(14h)
M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care
(23h)
Charta Health Raises $55M to Establish Pre-Claim Ground Truth Across Providers and Payers
(1d)
Google Cloud Launches Gemini for Healthcare: Unifying Payer and Provider Workflows Across Epic, Oracle Health, and MCP Connectors
(1d)
Zus Health Secures $33M to Scale AI-Native Health Data Infrastructure Beyond Legacy EHR Silos
(1d)
Ohio State Wexner Medical Center and Microsoft Ink 5-Year Partnership to Co-Develop the Smart Hospital of the Future
(1d)
GoodRx Launches MCP Integration with Google Cloud Gemini for Healthcare: Real-Time Prescription Pricing at the Point of Care
(1d)
Insights: Pink Sheet
Why The EU JCA For AstraZeneca’s Etcamah Took More Than 100 Days
(4h)
Fast Approval, Delayed Start? EU Speeds Modifications To Clear Trial-Blocking Conditions
(4h)
WuXi AppTec Removed From 1260H List, For Now
(13h)
US FDA Reorg Will Help Address ‘Surge’ In Cell, Gene Therapy Facility Inspections
(20h)
Operation TrialBlazer: US FDA’s Expedited IND Pilot Draws 100+ Applications
(20h)
US FDA Seeking Ideas To Avoid Data Use Problems When RWE Included In Application Reviews
(23h)
Senate Committee To Vote On US FDA Commissioner Nominee Before Dem Takeover
(1d)
AstraZeneca’s Potential Blockbuster Baxdrostat Nears EU Verdict After US Win
(1d)
Innovent Awaits EMA Verdict On Sintilimab After EU JCA Collapse And US Rejection
(1d)
US FDA Defines Risk-Based Potency Approach To Cell and Gene Therapy
(1d)
BioXconomy
Optimizing the Affordability Journey: Insights from a Real-World Brand Case Study
(20h)
GoodRx partners with Google Cloud to bring prescription savings into Gemini for healthcare
(3h)
Veristat, Clene use AI to speed up ALS drug application by 80%
(3h)
Build-a-biotech: Transitioning from academia to commercialization
(7h)
Tighter rules with COINS, DOJ-HHS and EHDS
(22h)
Biopharma firms tap new legal and compliance leads
(23h)
Guangzhou Innogen Pharmaceutical Group presents at BIO-Europe 2026
(23h)
Better data use and diversity engagement could boost UK trial participation
(1d)
Life Sciences Pricing & Contracting West
(1d)
State prescription affordability boards miss true patient cost causes
(1d)
BioCentury
PepGen’s DM1 readout hints at functional payoff from splicing correction
(18h)
SITC 2026: Dual targeting, precise integration shape in vivo CAR T development
(20h)
FDA approvals on track for record year
(21h)
Boehringer in six-program tie-up with Sino: Deals Report
(1d)
Overton confirmation unlikely, Brenner under consideration as acting FDA commissioner
(1d)
Novartis’ full HORIZON data deepen doubts about Lp(a) as a target
(1d)
Dose-dependent liver fat reductions support CIDEB as a target in MASLD
(1d)
What the U.S. midterms mean for biopharma — a BioCentury podcast
(1d)
Second M&A deal for argenx gives it Unnatural Products’ macrocyclic peptide platform
(1d)
China’s first-in-class deals grow as U.S. investment curbs loom — a BioCentury podcast
(4d)
SCRIP
Oyster Therapeutics Raises $60m To Target Alzheimer’s With Protein Degraders
(2h)
Stock Watch: Lilly’s 52-Week High Meets Alnylam’s 52-Week Low
(2h)
Beam Eyes Risto-Cel BLA As Early As Year-End After Positive Sickle Cell Data
(8h)
ACR 2026: Can ImmuneOnco‘s Bispecific Take On Roche’s Gazyva In SLE?
(10h)
Divamics Targeting Differentiation In Application Of AI To Drug Design
(11h)
AASLD 2026: Regeneron, GSK, Merck Look To Bring Competition In MASH
(21h)
Finance Watch: Proximal Ventures Backs AI-Based Life Sciences Solutions With New Fund
(21h)
Q3 Earnings Roundup: Roivant, Ionis, Lundbeck
(22h)
Scientific Questions Remain As Aumseqa Heads For New EU Verdict Just Weeks After Revocation
(1d)
Boehringer Ready To File Survodutide But At What Threat To Obesity Leaders?
(1d)